MSHS | UCLA Health | Clinical Research Operations | Breast Cancer
Los Angeles, CA
Joined December 2024
- Tweets14
- Following37
- Followers8
- Likes12
Lauren R Zelman, MSHS retweeted
Lajos Pusztai, Christina Minami, and Hans Wildiers discussed "Breast Cancer in Older Adults" in an #SABCS24 Educational Session moderated by Mina Sedrak. @HansWildiers @minasedrakmd
Lauren R Zelman, MSHS retweeted
In the latest @Breastcancerorg podcast, @dradityabardia discusses Enhertu for metastatic hormone receptor-positive, HER2-low and ultralow breast cancer.
Listen here: bit.ly/41whhaD
Lauren R Zelman, MSHS retweeted
Adding CDK4/6 inhibitor palbociclib to anti-HER2 therapy + hormone therapy in HR+/HER2+ MBC resulted in a 15.2-month benefit in progression-free survival in the phase 3 AFT-38 PATNIA trial presented @ #SABCS24 by @Otto_DFCI.
Lauren R Zelman, MSHS retweeted
Perhaps you thought that was a wrap on On Location, but nope! @CParkMD of @uofl & @MedNewsWeek is now at #SABCS24βand our first episode is here with Drs @jamecancerdoc of @ClevelandClinic & Rena Callahan of @UCLAHealthJCCC. Check it out now! #bcsm onclive.com/view/sharing-theβ¦
Starting bright & early todayβοΈ at @MarlaLipsycMD Poster Spotlight highlighting ctDNA uses for MRD Testing, Tumor Evolution & Novel Technologies
Listening to @MarlaLipsycMD speak at the Educational Session: Case Based Clinical Approach to ER Positive Metastatic Breast Cancer -Β In honor of Dr. V. Craig Jordan.
Fascinating discussion!
@SABCSSanAntonio #SABCS24
#UCLAJCCC
So proud of you, @minasedrakmd
Today at @SABCSSanAntonio, we are proud to honor 5 exceptional leaders for their groundbreaking work in advancing our understanding of breast cancer risk, metastasis, personalized treatments & education. Read more: bit.ly/4fco6Ba
#SABCS24
HAPPENING NOW: @UCLAHealthJCCC faculty and fellows are presenting their research posters!
@NikitaBacligMD
@AlkassisSamer
@DrKEMcCann
@SABCSSanAntonio #SABCS2024
Lauren R Zelman, MSHS retweeted
Former Komen grantee @dradityabardia presents new data from the phase 3 DESTINY-Breast06 trial @ #SABCS24. Trastuzumab-deruxtecan results in better progression-free survival compared to chemotherapy in people with HER2-low/ultra-low #breastcancer β even in aggressive cases.
Lauren R Zelman, MSHS retweeted
#SABCS24 Day 1 Highlights #CommunityOnc:
1. @FDAOncology Reviews recent approvals: #Ribociclib & #Inavolisib
2. #PADMA: HR+ ET + CDK4/6i vs Chemo 1L
3. #DB06: HR+ TDXd
4. #KN522: biomarker analysis
@SABCSSanAntonio @AACR #bcsm #OncTwitter
1/5
JUST NOW: @dradityabardia presented the updated results of DESTINY-Breast06 at @SABCSSanAntonio
@UCLAHealthJCCC
#SABCS24
Looking forward to being @SABCSSanAntonio to watch UCLA Faculty present the latest breast cancer research!
@dradityabardia
@MarlaLipsycMD
uclahealth.org/news/release/β¦
Lauren R Zelman, MSHS retweeted
Case Based Clinical Approach to ER Positive Metastatic Breast Cancer:
Michael Oliphant, Aditya Bardia, @NeilVasan, and Dan Stover will address this topic in an educational session at #SABCS24 (Dec 10-13). Learn more:
bit.ly/49nUHmw
@Mike_Oli @dradityabardia @StoverLab
